Predictors of success and risk factors for attrition in the use of intracavernous injection

Journal of Urology

Volumn 157, Issue 5, 1997, Pages 1681-1686

  Gupta, Ruchira ^a   Kirschen, Jill ^a   Barrow II, Robert C ^a   Eid, Jean Francois ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

drugs; impotence; injection; patient dropouts; prostaglandins E

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1;

ADULT; ARTICLE; FOLLOW UP; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATIENT COUNSELING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0030976022     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64834-1     Document Type: Article

References (23)

1. Brindley, G. S.: Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Brit. J. Physiol., 143: 332, 1983.
2. Abozeid, M. A., Juenemann, K.-P., Luo, J.-A., Lue, T. F., Yen, T.-S. B. and Tanagho, E. A.: Chronic papaverine treatment: the effect of repeated injections on the simian erectile response and penile tissue. J. Urol., 138: 1263, 1987.
3. Linet, O. I. and Ogrinc, F. G.: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. New Engl. J. Med., 334: 873, 1996.
4. Bennett, A. H., Carpenter, A. J. and Barada, J. H.: An improved vasoactive drug combination for a pharmacological erection program. J. Urol., 146: 1564, 1991.
5. Stief, C. G. and Wetterauer, U.: Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery. J. Urol., 140: 1415, 1988.
6. Keogh E. J., Watters, G. R., Earle, C. M., Carati, C. J., Wisniewski, Z. S., Tulloch, A. G. S. and Lord, D. J.: Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial. J. Urol., 142: 726, 1989.
7. Szasz, G., Stevenson, R. W., Lee, L. and Sanders, H. D.: Induction of penile erection by intracavernosal injection: a double-blind comparison of phenoxybenzamine versus papaverine-phentolamine versus saline. Arch. Sex. Behav., 16: 371, 1987.
8. Floth, A. and Schramek, P.: Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J. Urol., 145: 56, 1991.
9. Allen, R. P., Engel, R. M., Smolev, J. K. and Brendler, C. B.: Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1. J. Urol., 148: 1181, 1992.
10. Watters, G. R., Keogh, E. J., Earle, C. M., Carati, C. J., Wisniewski, Z. S., Tulloch, A. G. S. and Lord, D. J.: Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs. J. Urol., 140: 1417, 1988.
11. Irwin, M. B. and Kata, E. J.: High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology, 43: 84, 1994.
12. Althof, S. E., Turner, L. A., Levine, S. B., Risen, C., Kursh, E., Bodner, D. and Resnick, M.: Why do so many people drop out from auto-injection therapy for impotence? J. Sex Mar. Ther., 15: 121, 1989.
13. Sidi, A. A., Reddy, P. K. and Chen, K. K.: Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J. Urol., 140: 293, 1988.
14. Hollander, J. B., Gonzalez, J. and Norman, T.: Patient satisfaction with pharmacologic erection program. Urology, 39: 439, 1992.
15. Weiss, J. N., Badlani, G. H., Ravalli, R. and Brettschneider, N.: Reasons for high drop-out rate with self injection therapy for impotence. Int. J. Impotence Res., 6: 171, 1994.
16. Armstrong, D. K., Convery, A. G. and Dinsmore, W. W.: Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction. Brit. J. Urol., 74: 99, 1994.
17. Gerber, G. S. and Levine, L. A.: Pharmacological erection program using prostaglandin E1. J. Urol., 146: 786, 1991.
18. Weidner, W., Schroeder-Printzen, I., Fischer, C., Rudnick, J., Altinkilic, B. and Brahler, E.: Experience in the treatment of erectile dysfunction using the intracavernosal injection of papaverine. World J. Urol., 10: 179, 1992.
19. Montorsi, F., Guazzoni, G., Bergamaschi, F., Orlandini, A., Da Pozzo, L., Barbieri, L. and Rigatti, P.: Intracavernous vasoactive pharmacotherapy: the impact of a new self-injection device. J. Urol., 150: 1829, 1993.
20. Virag, R., Shoukry, K., Floresco, J., Nollet, F. and Greco, E.: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J. Urol., 145: 287, 1991.
21. Robinette, M. A. and Moffat, M. J.: Intracorporal injection of papaverine and phentolamine in the management of impotence. Brit. J. Urol., 58: 692, 1986.
22. Kerfoot, W. W. and Carson, C. C.: Pharmacologically induced erections among geriatric men. J. Urol., 146: 1022, 1991.
23. Girdley, F. M., Bruskewitz, R. C., Feyzi, J., Graversen, P. H. and Gasser, T. C.: Intracavernous self-injection for impotence: a long term therapeutic option? Experience in 78 patients. J. Urol., 140: 972, 1988.